Ushering in Neoadjuvant Immune Checkpoint Inhibitors for Mucosal Head and Neck Squamous Cell Carcinoma

Melina J. Windon, Nabil F. Saba, Moran Amit

Research output: Contribution to journalComment/debate

1 Scopus citations
Original languageEnglish
Pages (from-to)625-626
Number of pages2
JournalJAMA Otolaryngology - Head and Neck Surgery
Volume151
Issue number6
DOIs
StatePublished - Jun 12 2025

Funding

Conflict of Interest Disclosures: Dr Saba reports personal fees from AstraZeneca, Eisai Medical, Exelixis/Merck, Merck, EMD Serono, Pfizer, Kura, Vaccinex, CUE, BionTech, GSK, TOSK, Seagen, Flamingo, Infinity, Inovio, Aveo, Medscape, Onclive, UpToDate, BMS, Cornerstone, Celldex, Surface Oncology, Urogen, Astex, Imugene, Faron Pharmaceutical, Coherus, Adagene, Fulgent Springer, Nanobiotix, and Taiho and funding from Exelixis and BMS outside the submitted work. No other disclosures were reported.

FundersFunder number
GlaxoSmithKline
TOSK
Exelixis Inc.
Bamfield Marine Sciences Centre

    ASJC Scopus subject areas

    • Surgery
    • Otorhinolaryngology

    Fingerprint

    Dive into the research topics of 'Ushering in Neoadjuvant Immune Checkpoint Inhibitors for Mucosal Head and Neck Squamous Cell Carcinoma'. Together they form a unique fingerprint.

    Cite this